LABORATORY RESEARCH USE ONLY. NOT INTENDED FOR CONSUMPTION.

CJC-1295 with DAC — Published Research

Reviewed by: Elizabeth D.| Last updated: April 29, 2026|For laboratory reference only

← Back to CJC-1295 with DAC product page

How to read this CJC-1295 with DAC research page

This page summarizes CJC-1295 with DAC literature by experimental theme, including albumin-binding chemistry, modified GRF analog design, and model-system pharmacokinetic research. It is a literature map, not a protocol or human-use resource.

  • Chemistry focus: references are organized around DAC linker behavior, albumin binding, and receptor-signaling models.
  • Research framing: summaries describe published experimental models and should not be read as product claims or intended uses.
  • Documentation links: compare the catalog listing, COA hub, and research framework.

Panda Peptides products are for research use only. No dosing, administration, reconstitution, treatment, hormone-use, or human-use guidance is provided.

Research Library

Published research on CJC-1295 with DAC — for educational purposes only

Drug Affinity Complex (DAC) Albumin-Binding Technology

The DAC technology utilizes a reactive maleimide linker attached to the peptide that covalently binds to Cys34 of circulating serum albumin. This prevents glomerular filtration (albumin MW ~66 kDa exceeds renal threshold) and protects the peptide from proteolysis. The conjugation reaction is essentially irreversible under physiological conditions. Pharmacokinetic studies in animal models show that >90% of CJC-1295-DAC becomes albumin-bound within minutes. For laboratory research use only.

Jette L et al. “hGRF(1-29)-albumin bioconjugates activate GRF receptor signaling in rat models.” Endocrinology. 2005. PubMed

Receptor pharmacology overview

CJC-1295 is a modified GRF(1-29) analog that activates a class B receptor pathway in pituitary models. Receptor activation stimulates Gαs-mediated cAMP signaling and downstream secretory responses. The four amino acid substitutions (Ala2, Gln8, Ala15, Leu27) confer resistance to DPP-IV cleavage and improve receptor binding affinity compared to native GRF(1-29). For laboratory research use only.

Teichman SL et al. “Prolonged signaling effects of CJC-1295, a long-acting GRF analog.” J Clin Endocrinol Metab. 2006. PubMed

CJC-1295 in GRF-knockout mouse models

Studies using GRF-knockout mice—which have severe GH deficiency, dwarfism, and virtually undetectable IGF-1—demonstrated that CJC-1295 exposure partially restored somatic growth. Exposure increased body weight, femur length, and pituitary GH mRNA expression. The results confirmed that the somatotroph population in GRF-KO mice retained functional target receptors capable of responding to exogenous GRF analogs despite the absence of endogenous upstream peptide signaling. For laboratory research use only.

Alba M et al. “Exposure of CJC-1295, a long-acting GRF analog, normalizes growth in the GRF-knockout mouse.” Am J Physiol Endocrinol Metab. 2006. PubMed

Continue reviewing CJC-1295 with DAC

Use the research references above alongside Panda’s batch documentation and catalog specifications.

Disclaimer: All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use only. This page is provided for research-reference and documentation review only.

Reviewed by

Elizabeth D.

Research content reviewer focused on peptide literature review, documentation quality, and reference completeness.

Editorial Review

Reviewed by Elizabeth D. and James S. — Panda Peptides Research Team.

Last reviewed: May 2026.

This content summarizes published laboratory literature for research-reference purposes only. Products referenced by Panda Peptides are sold strictly for controlled laboratory, analytical, or reference use and are not consumer products.